These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 2170273)

  • 1. Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture.
    Erdös EG
    Hypertension; 1990 Oct; 16(4):363-70. PubMed ID: 2170273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Structure and physiological significance of angiotensin converting enzyme domains].
    Eliseeva IuE; Kugaevskaia EV
    Biomed Khim; 2009; 55(4):397-414. PubMed ID: 20000120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the N-terminal sequence of ACE on the properties of its C-domain.
    Marcic B; Deddish PA; Jackman HL; Erdös EG; Tan F
    Hypertension; 2000 Jul; 36(1):116-21. PubMed ID: 10904022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Structural and functional characteristics of angiotensin converting enzyme].
    Eliseeva IuE
    Bioorg Khim; 1998 Apr; 24(4):262-70. PubMed ID: 9612568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin converting enzyme: implications from molecular biology for its physiological functions.
    Hooper NM
    Int J Biochem; 1991; 23(7-8):641-7. PubMed ID: 1650717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
    van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
    Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do studies with ACE N- and C-domain-selective inhibitors provide evidence for a non-ACE, non-chymase angiotensin II-forming pathway?
    Husain A; Li M; Graham RM
    Circ Res; 2003 Jul; 93(2):91-3. PubMed ID: 12881473
    [No Abstract]   [Full Text] [Related]  

  • 8. Zinc, angiotensin I-converting enzyme and hypertension.
    Lockett CJ; Reyes AJ; Leary WP; Alcocer L; Olhaberry JV
    S Afr Med J; 1983 Dec; 64(26):1022-4. PubMed ID: 6316570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible involvement of angiotensin I-converting enzyme in the inactivation of bradykinin by intact macrophages.
    Nagaoka I; Yamashita T
    Biochim Biophys Acta; 1986 Apr; 886(2):231-42. PubMed ID: 3008853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.
    Minshall RD; Tan F; Nakamura F; Rabito SF; Becker RP; Marcic B; Erdös EG
    Circ Res; 1997 Nov; 81(5):848-56. PubMed ID: 9351459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides.
    Cotton J; Hayashi MA; Cuniasse P; Vazeux G; Ianzer D; De Camargo AC; Dive V
    Biochemistry; 2002 May; 41(19):6065-71. PubMed ID: 11994001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative properties of angiotensin-converting enzyme inhibitors: relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications.
    Nash DT
    Am J Cardiol; 1992 Apr; 69(10):26C-32C. PubMed ID: 1312295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype.
    van Esch JH; van Gool JM; de Bruin RJ; Payne JR; Montgomery HE; Hectors M; Deinum J; Dive V; Jan Danser AH
    J Hypertens; 2008 Apr; 26(4):706-13. PubMed ID: 18327080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New aspects on angiotensin-converting enzyme: from gene to disease.
    Baudin B
    Clin Chem Lab Med; 2002 Mar; 40(3):256-65. PubMed ID: 12005216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the first non-insect invertebrate functional angiotensin-converting enzyme (ACE): leech TtACE resembles the N-domain of mammalian ACE.
    Rivière G; Michaud A; Deloffre L; Vandenbulcke F; Levoye A; Breton C; Corvol P; Salzet M; Vieau D
    Biochem J; 2004 Sep; 382(Pt 2):565-73. PubMed ID: 15175004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme.
    Perich RB; Jackson B; Johnston CI
    Eur J Pharmacol; 1994 Feb; 266(3):201-11. PubMed ID: 8174603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drosophila melanogaster angiotensin I-converting enzyme expressed in Pichia pastoris resembles the C domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity.
    Williams TA; Michaud A; Houard X; Chauvet MT; Soubrier F; Corvol P
    Biochem J; 1996 Aug; 318 ( Pt 1)(Pt 1):125-31. PubMed ID: 8761461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joseph Rudinger memorial lecture: Unexpected functions of angiotensin converting enzyme, beyond its enzymatic activity.
    Martinez J
    J Pept Sci; 2017 Oct; 23(10):741-748. PubMed ID: 28626916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
    Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
    Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of domain-selective angiotensin I-converting enzyme inhibitors.
    Redelinghuys P; Nchinda AT; Sturrock ED
    Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.